Baker Bros. Advisors LP Summit Therapeutics Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 33,722,974 shares of SMMT stock, worth $620 Million. This represents 7.27% of its overall portfolio holdings.
Number of Shares
33,722,974
Previous 24,424,865
38.07%
Holding current value
$620 Million
Previous $471 Million
52.31%
% of portfolio
7.27%
Previous 5.62%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
259Shares Held
90.4MCall Options Held
4.71MPut Options Held
3.17M-
Vanguard Group Inc Valley Forge, PA8.67MShares$160 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$145 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$73.9 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$71.8 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.93MShares$54 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.7B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...